Community Awareness, Resources and Education (CARE II): Project 3

This study is currently recruiting participants.
Verified April 2014 by Ohio State University Comprehensive Cancer Center
Sponsor:
Collaborators:
University of Michigan
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Electra Paskett, Ohio State University Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01299714
First received: February 15, 2011
Last updated: April 10, 2014
Last verified: April 2014
  Purpose

Researchers at The Ohio State University and the University of Michigan are working together to understand cancer of the cervix. One of the areas they are studying is how stress you may experience in your life effects the way you respond to GARDASIL®. GARDASIL® is a vaccine approved by the Food and Drug Administration (FDA) to prevent some types of Human Papillomavirus (HPV) infection which can cause cancer of the cervix. Participants are being recruited from the Appalachian region of Ohio.


Condition
Uterine Cervical Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Community Awareness, Resources and Education (CARE II): Project 3

Resource links provided by NLM:


Further study details as provided by Ohio State University Comprehensive Cancer Center:

Primary Outcome Measures:
  • serum antibody levels for HPV 6,11,16 and 18 [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • serum antibody levels for Epstein-Barr Virus (EBV) [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Center for Epidemiological Studies - Depression (CES-D) Scale Score [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • perceived stress [ Time Frame: 12-months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

serum, Pap specimen, cervical specimen for HPV analysis, oral rinse specimen, saliva specimen


Estimated Enrollment: 438
Study Start Date: February 2011
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Detailed Description:

A quadrivalent HPV 6, 11, 16, 18 vaccine (GARDASIL®) has been approved for use among women age 9-26 years to prevent cervical/vaginal/vulvar cancer and genital warts. The efficacy of the vaccine has been demonstrated in clinical trial settings, but the effectiveness of this vaccine has not been tested in clinical practice settings. Patients experiencing greater stress have a reduced capacity to mount an immune response to other types of vaccine. The same phenomenon is likely to exist for Gardasil, but there are no data. The impact of psychological stress on the immune response to a vaccine is proposed to act via health behaviors (multiple lifetime sexual partners, never using condoms, prior abnormal Pap smear, smoking, and HPV infection) or by direct dysregulation of the immune system. We have found higher rates of cervical HPV in Appalachian Ohio women, higher rates of abnormal cervical cytology, and very high rates of psychological stress compared to urban and suburban women. The goal of this study is to determine if, in women age 18-26 years given GARDASIL® vaccine, serum HPV 6/11/16/18 antibody response is altered by stress. This will be accomplished by a study of 432 women age 18-26 years who report full range of life stressors recruited from Appalachian Ohio. All participants will receive the GARDASIL® vaccine at baseline, two months, and six months. Prior to vaccination questionnaire data related to HPV exposure risk behaviors and psychological stressors will be collected. Cervical samples will be collected for cytology and HPV testing. Serum samples will be collected for HPV 6, 11, 16 and 18 antibody assays at baseline and month 12. The questionnaire data and serum samples will be repeated at 12 months. The primary outcome measure is the difference in serum antibodies to HPV 6, 11, 16 and 18 at baseline and month 12. The variables of interest are perceived stress, sexual behaviors, socioeconomic status, access to health care (health insurance yes/no), smoking, Appalachian self-identity, HPV cervical status at baseline, and past history abnormal cervical cytology, as proposed in a psychoneuroimmunology model. In this model, Appalachian Self-Identity, socioeconomic status, loneliness, health care access, and coping are proposed to contribute to a woman's perceived stress. The impact of perceived stress on immune response to Gardasil vaccination can be by health behaviors such as multiple lifetime sexual partners (>4), never using condoms, prior abnormal Pap smear, smoking, and HPV status at the time of vaccination. Perceived stress can have a direct physiologic impact on the immune response by creating immune dysregulation as measured by increased EBV VCA-IgG titers. Depressive symptoms can mediate the impact of perceived stress on immune function. If psychological stress is found to modulate the immune response to GARDASIL®, then we can determine if the modulation reduces the clinical effectiveness of the vaccine and examine methods to limit the impact of stress.

  Eligibility

Ages Eligible for Study:   18 Years to 26 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Participants will be female, aged 18 - 26 years, residing in an Appalachian region, with no history of HPV vaccination.

Criteria

Inclusion Criteria:

  • Female
  • 18-26 years of age
  • Resident of an Appalachian county
  • Intact cervix
  • Able to read and understand English
  • Cognitively able to provide informed consent
  • Willing to come for four clinic visits

Exclusion Criteria:

  • Prior history of cervical cancer
  • Prior history of a cervical lesion treated with cryotherapy or any form of surgical removal of a portion of the cervix to treat CIN
  • No cervix
  • Pregnant or planning to become pregnant in the next year
  • History of immune disorder: auto-immune, primary immune or acquired
  • Any contra-indications for the GARDASIL® vaccine series
  • Taking immune suppressive medications
  • Any prior exposure to an HPV vaccine of any type
  • Planning to move out of the immediate area in the next year
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01299714

Contacts
Contact: Nita Y Williams, BS 614-293-7280 CARE.Project3@osumc.edu

Locations
United States, Ohio
Recruiting
Athens, Ohio, United States, 45701
Recruiting
Gallipolis, Ohio, United States, 45631
Recruiting
Logan, Ohio, United States, 43138
Recruiting
Pomeroy, Ohio, United States, 45769
Sponsors and Collaborators
Electra Paskett
University of Michigan
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Mack T Ruffin, IV, MD, MPH University of Michigan
Study Director: Electra D Paskett, PhD Ohio State University
  More Information

Additional Information:
No publications provided

Responsible Party: Electra Paskett, Marion N. Rowley Professor of Cancer Research and Director-Division of Cancer Prevention and Control, Ohio State University Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT01299714     History of Changes
Other Study ID Numbers: OSU-10096, P50CA105632, OSU-10096
Study First Received: February 15, 2011
Last Updated: April 10, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Ohio State University Comprehensive Cancer Center:
Human Papilloma Virus
vaccine
stress
cervical cancer
GARDASIL

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female

ClinicalTrials.gov processed this record on April 17, 2014